US Bancorp’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $68.5K | Sell |
840
-197
| -19% | -$14.2K | ﹤0.01% | 2647 |
|
|
2026
Q1 | $70.7K | Sell |
1,037
-203
| -16% | -$14.4K | ﹤0.01% | 2551 |
|
|
2025
Q4 | $94.2K | Buy |
1,240
+151
| +14% | +$11K | ﹤0.01% | 2405 |
|
|
2025
Q3 | $66.8K | Sell |
1,089
-2,078
| -66% | -$108K | ﹤0.01% | 2532 |
|
|
2025
Q2 | $155K | Buy |
3,167
+1,979
| +167% | +$93.9K | ﹤0.01% | 2190 |
|
|
2025
Q1 | $60.5K | Sell |
1,188
-6,049
| -84% | -$302K | ﹤0.01% | 2649 |
|
|
2024
Q4 | $327K | Sell |
7,237
-172
| -2% | -$7.36K | ﹤0.01% | 1741 |
|
|
2024
Q3 | $275K | Sell |
7,409
-57
| -0.8% | -$1.91K | ﹤0.01% | 1862 |
|
|
2024
Q2 | $228K | Sell |
7,466
-479
| -6% | -$15.5K | ﹤0.01% | 1927 |
|
|
2024
Q1 | $231K | Sell |
7,945
-496
| -6% | -$13.9K | ﹤0.01% | 1930 |
|
|
2023
Q4 | $233K | Buy |
8,441
+2,769
| +49% | +$63.3K | ﹤0.01% | 1930 |
|
|
2023
Q3 | $127K | Sell |
5,672
-611
| -10% | -$22.7K | ﹤0.01% | 2032 |
|
|
2023
Q2 | $256K | Sell |
6,283
-2,123
| -25% | -$104K | ﹤0.01% | 1754 |
|
|
2023
Q1 | $407K | Buy |
8,406
+660
| +9% | +$30.2K | ﹤0.01% | 1505 |
|
|
2022
Q4 | $296K | Sell |
7,746
-539
| -7% | -$22.4K | ﹤0.01% | 1654 |
|
|
2022
Q3 | $416K | Sell |
8,285
-661
| -7% | -$32.4K | ﹤0.01% | 1480 |
|
|
2022
Q2 | $359K | Sell |
8,946
-311
| -3% | -$10.9K | ﹤0.01% | 1611 |
|
|
2022
Q1 | $345K | Buy |
9,257
+832
| +10% | +$32.1K | ﹤0.01% | 1701 |
|
|
2021
Q4 | $336K | Buy |
8,425
+1,219
| +17% | +$46.7K | ﹤0.01% | 1737 |
|
|
2021
Q3 | $268K | Buy |
7,206
+549
| +8% | +$22.6K | ﹤0.01% | 1837 |
|
|
2021
Q2 | $281K | Buy |
6,657
+588
| +10% | +$25.2K | ﹤0.01% | 1831 |
|
|
2021
Q1 | $288K | Buy |
6,069
+5,767
| +1,910% | +$342K | ﹤0.01% | 1768 |
|
|
2020
Q4 | $18K | Buy |
302
+216
| +251% | +$12.7K | ﹤0.01% | 2965 |
|
|
2020
Q3 | $4K | Buy |
86
+58
| +207% | +$2.86K | ﹤0.01% | 3364 |
|
|
2020
Q2 | $1K | Buy |
+28
| New | +$1.38K | ﹤0.01% | 3639 |
|
|
2019
Q3 | – | Sell |
-1,908
| Closed | -$86K | – | 3654 |
|
|
2019
Q2 | $86K | Sell |
1,908
-1,207
| -39% | -$47.7K | ﹤0.01% | 2290 |
|
|
2019
Q1 | $117K | Buy |
3,115
+264
| +9% | +$8.86K | ﹤0.01% | 2112 |
|
|
2018
Q4 | $98K | Buy |
2,851
+958
| +51% | +$34.4K | ﹤0.01% | 2133 |
|
|
2018
Q3 | $89K | Buy |
1,893
+160
| +9% | +$6.62K | ﹤0.01% | 2289 |
|
|
2018
Q2 | $58K | Buy |
+1,733
| New | +$54K | ﹤0.01% | 2509 |
|
|
2016
Q2 | – | Sell |
-7
| Closed | – | – | 3618 |
|
|
2016
Q1 | $0 | Buy |
+7
| New | +$121 | ﹤0.01% | 3628 |
|
|
2015
Q4 | – | Sell |
-696
| Closed | -$18K | – | 3685 |
|
|
2015
Q3 | $18K | Buy |
+696
| New | +$29.8K | ﹤0.01% | 2899 |
|
Other funds holding PTCT
RI
JT
US Bancorp's PTCT Position: Q2 2026 in Review
US Bancorp reduced its PTC Therapeutics (PTCT) stake by 19% in Q2 2026, selling an estimated $14.2K and leaving 840 shares worth $68.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2647.
US Bancorp first reported a position in PTCT in Q3 2015 and has held it in 32 quarters since. The position peaked at $416K in Q3 2022. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- US Bancorp held 840 shares of PTC Therapeutics worth $68.5K as of Q2 2026.
- US Bancorp sold 197 PTC Therapeutics shares in Q2 2026, an estimated $14.2K.
- PTC Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #2647 holding.
- US Bancorp first reported a position in PTC Therapeutics in Q3 2015 and has held it in 32 quarters since.
- US Bancorp's PTC Therapeutics position peaked at $416K in Q3 2022.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.